KLOW does not use a separate female dose
A New Wave in the Pharmaceutical Sector: With growing interest and reliance on GLP-1 drugs, the pharmaceutical sector could see an impetus in the research and development of not only newer GLP-1 agonists but also other drugs that can impact both glucose regulation and weight management
These results aligned with those of Podolsky et al
In double-blind studies, neither participants nor doctors know who receives the placebo or the active medication
Altered composition of gut microbiota in depression: a systematic review
Additionally, comprehensive evaluation of long-term safety, pharmacokinetics, bioavailability, and drug-interaction profiles remains essential before such combinational or adjunctive therapies can be translated into clinical PD management (Shahpiri et al., 2016